The FDA is due to decide by 10 August whether it will approve a second CAR-T therapy from Gilead’s Kite unit intended to treat mantle cell lymphoma (MCL).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,